Mehdi Mesri

National Cancer Institute — Malaysia

Chemistry · Physical Sciences

49h-index16.7kcitations120works18.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Proteomics Techniques and Applications(44), Cancer Genomics and Diagnostics(25), Mass Spectrometry Techniques and Applications(19), Ferroptosis and cancer prognosis(14), Metabolomics and Mass Spectrometry Studies(10)

Publications113 total

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures
Cancer Cell·2025· 2 citedOpen Access
Proteomic-based stemness score measures oncogenic dedifferentiation and enables the identification of druggable targets
Cell Genomics·2025· 3 citedOpen Access
Multi-scale signaling and tumor evolution in high-grade gliomas
Cancer Cell·2024· 39 citedOpen Access
Comprehensive proteogenomic characterization of rare kidney tumors
Cell Reports Medicine·2024· 39 citedOpen Access
Abstract LB004: Deciphering oncogenic dedifferentiation: A proteomic approach to quantifying stemness scores and unveiling druggable targets
Cancer Research·2024
Abstract 3955: A proteogenomic study of high-grade glioma among adolescents and young adults
Cancer Research·2024
Abstract 1852: NCI’s Clinical Proteomic Tumor Analysis Consortium: A proteogenomic cancer analysis program
Cancer Research·2024· 2 cited
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
Cell·2024· 8 citedOpen Access
EPCO-53. MULTI-SCALE REGULATION OF SIGNALING CASCADES AND TUMOR EVOLUTION IN HIGH GRADE ASTROCYTOMAS
Neuro-Oncology·2023Open Access
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
Cancer Cell·2023· 90 citedOpen Access
Deep learning integrates histopathology and proteogenomics at a pan-cancer level
Cell Reports Medicine·2023· 30 citedOpen Access
Proteogenomic insights suggest druggable pathways in endometrial carcinoma
Cancer Cell·2023· 44 citedOpen Access
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
Cell·2023· 83 citedOpen Access
Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation
Cell·2023· 156 citedOpen Access
Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma
Nature Communications·2023· 3 citedOpen Access
Abstract LB061: Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets
Cancer Research·2023
Abstract 2019: NCI’s clinical proteomic tumor analysis consortium analysis tools and resources
Cancer Research·2023
Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma
Nature Communications·2023· 40 citedOpen Access
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Cancer Cell·2022· 184 citedOpen Access
Neoplastic cell enrichment of tumor tissues using coring and laser microdissection for proteomic and genomic analyses of pancreatic ductal adenocarcinoma
Clinical Proteomics·2022· 4 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Henry Rodriguez(36), Christopher R. Kinsinger(27), Steven A. Carr(25), Amanda G. Paulovich(23), Tara Hiltke(23), David Fenyö(22), D.R. Mani(21), Bing Zhang(20), Li Ding(19), Emily S. Boja(19), Pei Wang(17), Karin Rodland(16), D.C. Liebler(16), Kelly V. Ruggles(15), Karl R. Clauser(15), Matthew J. Ellis(15), Michael A. Gillette(14), Hui Zhang(14), Richard Smith(14), Mathangi Thiagarajan(14)